Merck & Co., Inc. (MRK) Holdings Decreased by CIBC Private Wealth Group LLC

CIBC Private Wealth Group LLC trimmed its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 15.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,102,056 shares of the company’s stock after selling 392,038 shares during the period. CIBC Private Wealth Group LLC owned approximately 0.08% of Merck & Co., Inc. worth $160,618,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Contravisory Investment Management Inc. grew its position in shares of Merck & Co., Inc. by 186.4% during the 4th quarter. Contravisory Investment Management Inc. now owns 653 shares of the company’s stock valued at $50,000 after acquiring an additional 425 shares during the period. Arlington Partners LLC lifted its stake in shares of Merck & Co., Inc. by 93.5% during the 4th quarter. Arlington Partners LLC now owns 828 shares of the company’s stock valued at $63,000 after buying an additional 400 shares in the last quarter. Financial Gravity Companies Inc. purchased a new position in shares of Merck & Co., Inc. during the 4th quarter valued at $66,000. Advisors Preferred LLC purchased a new position in shares of Merck & Co., Inc. during the 4th quarter valued at $66,000. Finally, Transamerica Financial Advisors Inc. lifted its stake in shares of Merck & Co., Inc. by 61.4% during the 4th quarter. Transamerica Financial Advisors Inc. now owns 1,293 shares of the company’s stock valued at $99,000 after buying an additional 492 shares in the last quarter. Hedge funds and other institutional investors own 73.51% of the company’s stock.

In other news, EVP Robert M. Davis sold 192,572 shares of the company’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $82.38, for a total value of $15,864,081.36. Following the completion of the sale, the executive vice president now owns 330,232 shares of the company’s stock, valued at approximately $27,204,512.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Merck & Co., Inc. bought 4,121,683 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were purchased at an average cost of $16.00 per share, with a total value of $65,946,928.00. The disclosure for this purchase can be found here. Insiders sold a total of 1,094,632 shares of company stock worth $87,840,652 over the last 90 days. Insiders own 0.32% of the company’s stock.

Shares of NYSE:MRK opened at $76.63 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.92 and a current ratio of 1.17. The stock has a market cap of $206.04 billion, a P/E ratio of 17.66, a PEG ratio of 1.81 and a beta of 0.63. Merck & Co., Inc. has a 12 month low of $56.26 and a 12 month high of $83.85.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Friday, February 1st. The company reported $1.04 EPS for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.01. The business had revenue of $11 billion for the quarter, compared to the consensus estimate of $10.93 billion. Merck & Co., Inc. had a net margin of 14.71% and a return on equity of 36.83%. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.98 EPS. On average, equities analysts forecast that Merck & Co., Inc. will post 4.65 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, April 5th. Shareholders of record on Friday, March 15th were paid a $0.55 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $2.20 dividend on an annualized basis and a yield of 2.87%. Merck & Co., Inc.’s dividend payout ratio is currently 50.69%.

Several analysts have commented on MRK shares. BMO Capital Markets cut shares of Merck & Co., Inc. from an “outperform” rating to a “market perform” rating and set a $80.00 price target on the stock. in a research note on Wednesday, January 23rd. ValuEngine cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Thursday, April 18th. Zacks Investment Research upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $83.00 price target on the stock in a research note on Friday, January 4th. Cantor Fitzgerald restated a “buy” rating and issued a $95.00 target price on shares of Merck & Co., Inc. in a report on Friday, March 29th. Finally, Argus boosted their target price on shares of Merck & Co., Inc. to $95.00 and gave the stock a “buy” rating in a report on Wednesday, February 20th. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $80.55.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/04/27/cibc-private-wealth-group-llc-has-160-62-million-holdings-in-merck-co-inc-mrk.html.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

See Also: 52-Week High/Low

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.